58.70 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||58.55 x 800|
|Ask||83.00 x 1000|
|Day's Range||58.41 - 60.85|
|52 Week Range||25.00 - 82.35|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2017 - Nov 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.00|
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.
Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.
The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Warning! GuruFocus has detected 1 Warning Sign with SRDX. For the last quarter Surmodics Inc reported a revenue of $23.0 million, compared with the revenue of $20.06 million during the same period a year ago.
The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.
Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.